Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

ALK-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of ALK inhibitors. Thus, it is imperative for clinicians to screen appropriate patients for this driver mutation with a molecular testing platform capable of ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Viola W, Schrock, Alexa B, Bosemani, Thangavijayan, Benn, Bryan S, Ali, Siraj M, Ou, Sai-Hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234987/
https://www.ncbi.nlm.nih.gov/pubmed/30519133
http://dx.doi.org/10.2147/LCTT.S186804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234987/
https://www.ncbi.nlm.nih.gov/pubmed/30519133
http://dx.doi.org/10.2147/LCTT.S186804

Ejemplares similares